Commerce Bank Buys Shares of 34,501 Edwards Lifesciences Corporation $EW

Key Points

• Commerce Bank acquired 34,501 shares of Edwards Lifesciences during the second quarter, worth approximately $3.1 million. Institutional investors collectively own 79.46% of the company.
• Analyst sentiment remains positive, with 17 analysts rating EW a Buy and six assigning a Hold rating. The stock has a “Moderate Buy” consensus and an average price target of $100.27.
• Edwards Lifesciences reported quarterly EPS of $0.78, exceeding estimates by $0.04, while revenue rose 13.6% year over year to $1.74 billion. Shares opened at $90.53, near the middle of their 52-week range.

Commerce Bank purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 34,501 shares of the medical research company's stock, valued at approximately $3,121,000.

A number of other hedge funds have also modified their holdings of EW. BlackRock Inc. acquired a new position in Edwards Lifesciences in the second quarter valued at about $5,318,092,000. State Street Corp increased its position in shares of Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company's stock valued at $2,215,777,000 after acquiring an additional 371,892 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Edwards Lifesciences by 4.8% in the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company's stock valued at $1,857,934,000 after acquiring an additional 989,533 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $1,274,082,000. Finally, Norges Bank acquired a new position in shares of Edwards Lifesciences in the 4th quarter worth approximately $803,686,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business's stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares of the company's stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the company's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by company insiders.

Analyst Ratings Changes

EW has been the subject of a number of research analyst reports. Wall Street Zen cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Saturday, July 4th. Evercore restated an "outperform" rating and set a $100.00 price target on shares of Edwards Lifesciences in a research note on Monday, July 6th. Royal Bank Of Canada upped their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. TD Cowen restated a "buy" rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $100.27.

Edwards Lifesciences Trading Up 0.8%

NYSE EW opened at $90.53 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The firm has a market cap of $52.13 billion, a price-to-earnings ratio of 52.03, a PEG ratio of 2.25 and a beta of 0.85. The firm has a 50 day simple moving average of $89.30 and a 200-day simple moving average of $84.74. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm's revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source